Diet-derived ergothioneine induces necroptosis in colorectal cancer cells by activating the SIRT3/MLKL pathway

FEBS Lett. 2022 May;596(10):1313-1329. doi: 10.1002/1873-3468.14310. Epub 2022 Feb 14.

Abstract

Ergothioneine (Egt) is a dietary amino acid which acts as an antioxidant to protect against ageing-related diseases. We investigated the anti-cancer properties of Egt in colorectal cancer cells (CRC). Egt treatment exerted cytotoxicity in a dose-dependent manner, induced reactive oxygen species accumulation, loss of mitochondrial membrane potential and upregulation of the histone deacetylase SIRT3. Immunoblotting analysis indicated that the cell death occurred via necroptosis through activation of the RIP1/RIP3/MLKL pathway. An immunoprecipitation assay unveiled that the interaction between the terminal effector in necroptotic signalling MLKL and SIRT3 increased during the Egt treatment. SIRT3 gene silencing blocked the upregulation of MLKL and abolished the ability of Egt to induce necroptosis. The SIRT3-MLKL interaction may mediate the necroptotic effects of Egt in CRC, suggesting the potential of this dietary amino thione in the prevention of CRC.

Keywords: RIP1/RIP3/MLKL; SIRT3; colon cancer; ergothioneine; necroptosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis
  • Colorectal Neoplasms* / genetics
  • Diet
  • Ergothioneine* / pharmacology
  • Humans
  • Necroptosis
  • Protein Kinases / metabolism
  • Receptor-Interacting Protein Serine-Threonine Kinases / metabolism
  • Sirtuin 3* / genetics
  • Sirtuin 3* / metabolism

Substances

  • Ergothioneine
  • MLKL protein, human
  • Protein Kinases
  • Receptor-Interacting Protein Serine-Threonine Kinases
  • SIRT3 protein, human
  • Sirtuin 3